jmiks
- Pacira BioSciences (NASDAQ:PCRX) plummeted ~25% in Tuesday trading after the U.S. FDA approved a generic version of Exparel (bupivacaine liposome), a non-opioid used for post-surgery local anasthesia.
- The agency approved an abbreviated New Drug Application for a generic version from Hengrui Pharma.
- Exparel is by far Pacira’s biggest revenue driver. In Q1, it brought in $132M in revenue.